Edition:
India

Alexion And Zealand Pharma Announce Pact To Discover And Develop Peptide Therapies


Wednesday, 20 Mar 2019 

March 20 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.ZEALAND PHARMA A/S - COLLABORATION FURTHERS ALEXION'S COMPLEMENT LEADERSHIP WITH EXPANSION INTO PEPTIDE THERAPIES.ZEALAND-AGREEMENT PROVIDES ALEXION EXCLUSIVE WORLDWIDE LICENSES FOR 1 PRECLINICAL TARGET, OPTION FOR UP TO 3 ADDITIONAL TARGETS, IN COMPLEMENT PATHWAY.ZEALAND - TO RECEIVE UPFRONT PAYMENT OF $25 MILLION & EQUITY INVESTMENT OF $15 MILLION, WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT & ROYALTY PAYMENTS.ZEALAND PHARMA A/S - WILL LEAD JOINT DISCOVERY AND RESEARCH EFFORTS THROUGH PRECLINICAL STAGE.ZEALAND PHARMA A/S - ALEXION WILL LEAD DEVELOPMENT EFFORTS BEGINNING WITH IND FILING AND PHASE 1 STUDIES.ZEALAND PHARMA A/S - FOR LEAD TARGET, AGREEMENT PROVIDES POTENTIAL FOR DEVELOPMENT-RELATED MILESTONES OF UP TO $115 MILLION.ZEALAND-FOR LEAD TARGET AGREEMENT PROVIDES UP TO $495 MILLION IN SALES-RELATED MILESTONES, POTENTIAL FOR HIGH SINGLE- TO LOW DOUBLE-DIGIT ROYALTY PAYMENTS.